跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
诺和益 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Insulin Degludec and Liraglutide Injection
Approved
生物制品
Insulin Degludec and Liraglutide Injection
Novo Nordisk A/S
🇨🇳 National Medical Products Administration
Approval Date
Oct 26, 2021
Approval ID
8BYtPNYKzZX
Company
Novo Nordisk A/S
Type
生物制品
Approval Details
Approval Id
8BYtPNYKzZX
Approval Number
国药准字SJ20210026
Generic Name
德谷胰岛素利拉鲁肽注射液
Generic Name En
Insulin Degludec and Liraglutide Injection
Trade Name
诺和益
Drug Type
生物制品
Dosage Form
注射剂
Strength
每支3ml，含300 单位德谷胰岛素和10.8 mg利拉鲁肽
Reg Date
2021-10-26
Expired Date
2026-10-25
Company Name
Novo Nordisk A/S
Production Company Name
Novo Nordisk A/S
Company Detail Path
/organization/novo-nordisk-a-s
Production Company Detail Path
/organization/novo-nordisk-a-s
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Oct 26, 2021
Approval ID
8BYtPNYKzZX
Type
生物制品
Back to NMPA Approvals
